



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville, MD 20857

ANDA 91-077

Novel Laboratories, Inc.
Attention: Anu Radha Subramanian, Esq.
Head of Regulatory Affairs
400 Campus Drive
Somerset, NJ 08873

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 13, 2008, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Polyethylene Glycol 3350 Powder for Solution, 17 grams/Scoopful.

Reference is also made to the tentative approval letter issued by this office on September 24, 2009, and to your amendment dated September 24, 2009.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Polyethylene Glycol 3350 Powder for Solution, 17 grams/scoopful, to be bioequivalent to the reference listed drug, MiraLax Powder for Solution, 17 grams/Scoopful, of Schering Plough Healthcare Products, Inc.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Within 14 days of the date of this letter, submit updated content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the approved labeling. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission as **"Miscellaneous Correspondence - SPL for Approved ANDA 91-077."**

Sincerely yours,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research